Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results, Meets Estimates

Posted by Chris Copeland on Nov 5th, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, meeting analysts’ consensus estimates of ($0.38), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

Avexitide’s Phase III LUCIDITY trial met its primary and all secondary endpoints, including a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events versus placebo, with a favorable safety profile. Amylyx remains on track to submit an NDA by year-end and is preparing for a potential 2027 launch, subject to FDA review.
An oversubscribed equity offering generated $545 million in net proceeds, bringing cash and cash equivalents to $768 million at quarter-end. Management said the funds support NDA preparation, launch readiness, and pipeline development.
The company estimates about 160,000 people in the U.S. live with PBH and reports growing physician interest in treatment options; a PBH-specific ICD-10 code took effect in October. These market-size and demand assessments are based on Amylyx’s analyses and research.
Operating expenses rose 38% year over year to $49.7 million, reflecting higher trial spending and pre-commercialization costs; stock-based compensation also increased. The higher spending comes as Amylyx scales its commercial organization ahead of a possible launch.
Beyond avexitide, Amylyx is targeting a 2027 IND filing for AMX0318, while its AMX0114 ALS trial has advanced to enrollment in its fourth dose cohort. The company also reported progress on a research collaboration, but did not provide new efficacy results for these programs.

Amylyx Pharmaceuticals Stock Performance

AMLX traded down $1.78 during trading on Thursday, reaching $27.62. The company had a trading volume of 2,210,040 shares, compared to its average volume of 1,297,574. The business’s fifty day moving average price is $30.15 and its 200 day moving average price is $20.35. Amylyx Pharmaceuticals has a 12 month low of $10.83 and a 12 month high of $41.14.

Wall Street Analysts Forecast Growth

AMLX has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Tuesday. Mizuho increased their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Citigroup upped their target price on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. Guggenheim boosted their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Finally, Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.14.

Read Our Latest Stock Analysis on Amylyx Pharmaceuticals

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 9,536 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.46, for a total transaction of $309,538.56. Following the transaction, the insider directly owned 190,838 shares in the company, valued at $6,194,601.48. The trade was a 4.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director owned 782,881 shares in the company, valued at approximately $21,685,803.70. This trade represents a 3.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 60,374 shares of company stock worth $1,815,257. Company insiders own 10.90% of the company’s stock.